JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Occurrence and geodatabase mapping of three contaminants of emerging concern in receiving water and at effluent from waste water treatment plants - A first overview of the situation in the Republic of Ireland.

This constitutes the first study to address occurrence and geodatabase mapping of the anti-inflammatory drug diclofenac (DCL) and the natural (17-beta-estradiol or E2) and synthetic (17-alpha-ethynylestradiol or EE2) estrogenic hormones in Republic of Ireland receiving waters over the period 1999 to 2015. Among these data, 317 samples came from concentration studies, while 205 were from effect-based studies. Monitoring data came from 16 waste water treatment plants (WWTPs), 23 water bodies (including rivers, lakes, marine and transitional waters) and 7 from domestic locations. Out of approximately 1000 WWPTs in the Republic of Ireland, only 16 have been monitored for at least one of these compounds of emerging concern (CECs). Diclofenac is found in treated effluents from 5 WWTPs at levels at least as high as other European WWPTs, and sometime higher. Measurements of E2 and EE2 in WWPT effluents were rare and effluents were more often evaluated for total estrogens; these CECs were generally not detected using conventional analytical methods because of limits of detection being too high compared to environmental concentrations and WFD environmental quality standards. There was good agreement between occurrence of these CEC and regional drug dispensing data in Ireland. Mapping the aforementioned data onto appropriate river basin catchment management tools will inform predictive and simulated risk determinations to inform investment in infrastructure that is necessary to protect rivers and beaches and economic activities that rely on clean water. There is a pressing commensurate need to refine/develop new analytical methods with low levels of detection for future CEC intervention.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app